AI-generated content for educational purposes only. Not tax advice. Citations may contain errors — verify independently.
← Back to corpus

Software IP Contribution to Venture Fund: Remedial Allocations or Valuation Overreach?

High
—
🏢 Client 2026-03-27 22:00
I'm contributing a portfolio of software IP to a new venture fund structure — about $50 million fair market value with a $5 million tax basis. The fund will have me as the managing member with a 20% carry interest, plus three institutional LPs putting in $150 million cash. We're projecting the IP will generate substantial licensing revenue over the next seven years before we wind down. My tax advisor mentioned we need to pick a 704(c) method for handling my built-in gain, but honestly I got lost in the jargon. She threw out "traditional," "curative," and "remedial" as options. I understand there's $45 million of built-in gain that somehow needs to get allocated back to me for tax purposes, but I'm unclear on how these methods actually work in practice and what the real economic difference is. Here's what I care about: I want the LPs to get their full tax benefit from the cash they're putting in, because they're sophisticated and will walk if the structure screws up their returns. But I also don't want to get stuck with a massive tax bill in year three if we hit our revenue projections. What's the right 704(c) method for this situation, and what am I actually trading off between these three approaches?
⚡ Junior Advisor 2026-03-27 22:00
Look, the core issue here is straightforward: you have $45 million of built-in gain sitting in that IP, and under Section 704(c) and the regulations, that gain has to be allocated back to you when the partnership eventually recovers it — either through income or disposition. The three methods differ in how and when they force that allocation, and whether they create distortions for your LPs along the way. Traditional method is the simplest but probably wrong for your deal. When the IP generates licensing income, the partnership allocates that income under the operating agreement — let's say pro rata based on capital. But then Section 704(c) redirects enough of that income to you to match the built-in gain recovery. The problem? If the IP generates $10 million of licensing revenue in year one and your built-in gain eats up $8 million of it, your LPs only get credited with $2 million of income even though they're entitled to way more under the economic split. That's a ceiling rule problem — there's not enough income to give the LPs their full share and satisfy your built-in gain at the same time. Your institutional LPs will see their tax capital accounts lagging their economic capital accounts and they'll kill the deal. Curative tries to solve that by letting the partnership make curative allocations of other partnership income to the LPs — stuff that wouldn't normally go to them — to fix the distortion. That works if you've got other income streams to redirect, but you're describing a fund that's mostly going to generate licensing revenue from this IP. There's nothing to curate with. If the only material income item is the IP income itself, curative collapses back into traditional. You'd need operating income from portfolio companies or something else to shuffle around, and even then it only works if the timing lines up. Curative also doesn't let you use capital gains to cure ordinary income distortions, so depending on the character of your licensing revenue versus other fund income, you might still hit a wall. Remedial is the one that actually solves your problem, but it comes with a cost. Under Treasury Regulation 1.704-3(d), the partnership just creates tax allocations out of thin air — it books additional income to you to cover the built-in gain and simultaneously books offsetting deductions to the LPs, even if the partnership didn't actually generate that much income economically. So if the IP throws off $10 million of licensing income, the partnership can allocate the full economic share to your LPs under the operating agreement, then layer on remedial allocations: extra income to you for the built-in gain, extra deductions to the LPs to keep them whole. The LPs get their full tax basis step-up as if they'd funded the whole thing with cash. Your concern about a massive tax bill in year three — that's real under any method, but remedial at least doesn't screw the LPs in the process. The trade-off is you're accelerating tax income to yourself that doesn't correspond to cash, so you need to make sure the operating agreement gives you enough cash distributions to cover the liability. What does your distribution waterfall look like — are you getting tax distributions before the LPs hit their preferred return?
🛡️ Senior Advisor 2026-03-27 22:00
I think you're overcomplicating the curative piece and underselling the actual risk remedial creates for the client. Curative doesn't require some separate magic income stream — it just means when you have future partnership items that don't have Section 704(c) taint, you tilt those allocations away from their normal split to correct earlier ceiling rule distortions. In a fund structure that's going to have seven years of operating activity and then wind down, you'll have plenty of items to work with: management fees the GP entity earns, disposition gains when portfolio companies exit, possibly even expense allocations you can flip around. The question isn't whether curative can work mechanically — it's whether it can work fast enough that the LPs don't sit in a hole for three years waiting for the fix. But here's what worries me more about your answer: you just told a client to use remedial allocations without walking through what happens in an audit if the IRS decides the partnership didn't properly substantiate the built-in gain at formation. Remedial lets you create phantom income and phantom deductions — that's an examiner's red flag from day one. If the IRS challenges the $50 million valuation on contribution and says the IP was really worth $35 million, your built-in gain drops to $30 million, and now you've got $15 million of remedial allocations floating around that never should have existed. The LPs took deductions they weren't entitled to, and you took income that overstates your real built-in gain. That's not a rounding error — that's a mess. Did we get an independent appraisal of this IP at contribution, or are we working off the client's internal numbers? The other thing you glossed over is the character issue, and it matters a lot here. The client said licensing revenue — is that ordinary income or capital gain? If it's ordinary, and the fund later sells portfolio investments at long-term capital gain, remedial allocations have to match character. You can't use capital gain items to create remedial offsets against ordinary income distortions. So the LPs might get their full economic allocation of capital gains but still eat a reduced allocation of ordinary income from the IP if there's a ceiling rule problem in that bucket. We need to know what the revenue model actually looks like year by year and what other income is going to show up before we can tell the client remedial fixes everything. What's the timeline on closing this fund, and have you already ordered a valuation or are we still at the term sheet stage?
🏢 Client 2026-03-27 22:01
Wait, let me make sure I understand the actual risk here. You're saying if we go with remedial, the IRS could come back in an audit and challenge the $50 million valuation of the IP, and then suddenly we've got phantom deductions flowing to the LPs that shouldn't exist. But what's the realistic probability of that happening if we get a proper appraisal upfront? I mean, software IP valuations are inherently squishy — there's a range, not a single number. Are we talking about an audit risk where they're going to argue $50 million should have been $35 million, or are they only going to challenge it if we're wildly off-market? Here's what I'm trying to figure out: if I get a Big Four valuation firm to appraise the IP at contribution and they come back at $50 million with a defensible methodology, does that actually insulate us from this problem? Or is the issue that even with a clean appraisal, the IRS can second-guess it and we're stuck defending remedial allocations in Tax Court three years later? Because I'm happy to spend $100K on a bulletproof valuation if that makes the audit risk immaterial. But if we're saying the remedial method itself is inherently aggressive regardless of documentation, then I need to understand what the alternative is. On the character question — the licensing revenue is definitely ordinary income, at least for the first few years. We're licensing the IP to operating companies on annual or multi-year terms. But the fund will also be making direct investments in some of those licensees, so there should be capital gains down the road when we exit those positions. Are you saying remedial works for the capital gains bucket but not the ordinary income bucket, so I'm still stuck with ceiling rule problems on the licensing revenue even if we elect remedial? That seems like it defeats the whole purpose.
⚡ Junior Advisor 2026-03-27 22:01
I think you're conflating two different risks and we need to separate them. The valuation risk — can the IRS challenge your $50 million number — exists regardless of which 704(c) method you pick. Traditional, curative, remedial, it doesn't matter: if you contribute property with a claimed value of $50 million and a basis of $5 million, the IRS can examine whether that value is supportable. A Big Four appraisal absolutely helps, but it's not a force field. I've seen the Service challenge valuations that had Big Four opinions behind them, especially with intangibles where there's inherent subjectivity in the income projections. The difference is that under remedial, if the valuation falls apart, the consequences propagate through every year of phantom allocations you've already made. Under traditional or curative, a busted valuation just means you have less built-in gain to allocate — annoying, but not a multi-year cleanup problem with the LPs' tax returns. What my colleague is missing, though, is that the character matching issue doesn't kill remedial for you — it just means you need to track two separate 704(c) layers. The ordinary income from licensing gets remedial treatment in the ordinary bucket: you take extra ordinary income, LPs get offsetting ordinary deductions. The capital gains from portfolio exits get remedial treatment in the capital bucket: you take extra capital gain, LPs get offsetting capital loss or reduced capital gain. Treas. Reg. 1.704-3(d) specifically allows this — you just have to maintain separate calculations. It's administratively heavier and your K-1 preparers will hate you, but it's not prohibited. The real question is whether your fund administrator can actually handle that level of complexity, because I've seen partnerships elect remedial and then discover their accounting software can't track it correctly. But here's where I actually disagree with your framing: you keep asking what makes the audit risk "immaterial," and that's not the right standard. The risk isn't immaterial — it's manageable if you document correctly and price it into your decision. If you go remedial, you're making a bet that the valuation holds and the administrative complexity is worth it to keep the LPs happy. If you go curative, you're betting that over seven years you'll generate enough non-IP income to cure the distortions before the LPs revolt. There's no free lunch here. Which of those bets feels better to you given what you know about the fund's business model, and what's your appetite for having a footnote in the partnership agreement that warns the LPs their deductions depend on the contribution valuation being sustained?
🛡️ Senior Advisor 2026-03-27 22:01
I'm going to push back on the idea that the valuation risk is the same across all three methods — that's technically true but misleading in a way that matters for the client. Yes, the IRS can challenge a $50 million valuation no matter what 704(c) method you pick. But under traditional or curative, if they knock it down to $40 million, you just have $10 million less built-in gain to allocate going forward. The LPs never took deductions they weren't entitled to — they just got more partnership income than they would have if your number had held. That's a nothing-burger in an audit. Under remedial, those same LPs took actual deductions on their returns — real tax benefits they used to offset other income — and now the IRS is saying those deductions were overstated because the built-in gain was overstated. You're not just adjusting future allocations, you're potentially amending multiple years of LP returns and dealing with accuracy-related penalties if the original valuation was aggressive. That's a categorically different conversation with your investors. Here's the other thing that concerns me: you said the licensing revenue is ordinary income for the first few years, and you'll have capital gains later when portfolio companies exit. That means in years one through three — exactly the period you said you're worried about a massive tax bill — the remedial allocations are going to be creating ordinary income to you and ordinary deductions to the LPs. Those deductions are worth more to institutional LPs than capital losses would be, so that's good for them. But it also means if there's an audit adjustment, you're talking about ordinary deductions getting disallowed, which is the highest-scrutiny item in an IRS exam of a fund. I would want to see stress-test numbers before you commit to this: if the IP value gets knocked down by 20% in an exam, how much ordinary deduction gets clawed back from each LP, and does that create a litigation risk where they come after the GP for misrepresentation? Your fund documents probably have some indemnity provision that runs one way or the other on tax issues. The $100K valuation helps but it's not sufficient. What you actually need is a valuation that stress-tests the low end of the range and then you structure the contribution at a number you're confident represents the floor, not the midpoint. If the appraiser says the range is $40 million to $60 million and you contribute at $50 million, you're exposed. If they say the range is $45 million to $65 million and you contribute at $50 million, you're in much better shape. Have you had a preliminary conversation with a valuation firm yet, or are we speculating about what number they'd give you?
⚡ Junior Advisor 2026-03-27 22:02
I think you're creating a false choice between "safe valuation at the floor" and "aggressive valuation at the midpoint" that doesn't match how sophisticated LPs are actually going to evaluate this deal. If the client goes to a valuation firm and they come back with a range of $45 million to $65 million, and he then contributes the IP at $50 million, the LPs are going to ask why he's not contributing at $55 million or $60 million. They're putting in $150 million of cash at par — actual dollars with no valuation uncertainty — and they're going to expect him to contribute his IP at a number that reflects real economic value, not a defensive lowball to make the tax administration easier. If he shorts his own contribution value to avoid audit risk, he's diluting his equity stake in a way that makes the whole deal less attractive to him economically. The better way to think about this is that the valuation risk exists but it's not the driver. What actually matters is whether the remedial allocations create enough ongoing complexity and potential LP friction that it's worth structuring around. You mentioned indemnity provisions — sure, the fund docs will have tax representation and warranty provisions, but institutional LPs in venture funds know they're investing in a vehicle with a contributed IP asset and they price that risk in at the subscription stage. They're not going to sue the GP three years later because an IRS audit knocks $5 million off the valuation. They're going to sue if the GP misrepresented the existence of the IP or its legal ownership, not if a good-faith valuation ends up at the low end of a reasonable range. Here's what I'd actually focus on with the client: the ceiling rule problem under traditional method is real and immediate. If you generate $20 million of licensing revenue in year two and $15 million of it has to get allocated to you under Section 704(c), the LPs are only seeing $5 million of income when their economic share should be way higher. That's not an audit risk three years from now — that's a phone call from the LP advisory board in year two asking why their K-1s don't match the financial statements. Curative can work if you've got enough other items to shuffle, but you need to model it out year by year to see if the math actually works. Remedial solves that problem definitively, and the valuation risk is manageable if you do the work upfront. What's your expected licensing revenue in year one, and do you have any other partnership-level income we can use for curative allocations if we want to avoid remedial?
🛡️ Senior Advisor 2026-03-27 22:02
I think you're dramatically understating the reputational and practical consequences of getting the valuation wrong under remedial, and you're also giving the client bad advice about LP expectations. Institutional LPs absolutely do care about contributed property valuations — not because they're going to sue over a $5 million variance, but because overstated valuations directly affect their tax basis in the partnership and their ability to deduct losses or recognize gains on exit. If this fund underperforms and the LPs want to write down their investment or sell their interests at a loss, an inflated IP contribution value at formation reduces the loss they can recognize. They know that, which is why sophisticated LPs negotiate valuation floors and rights to challenge valuations in the partnership agreement. You're right that they won't sue over the IP's legal ownership, but you're wrong to think they'll just shrug off a scenario where their tax deductions get disallowed because the GP was aggressive on value. The other issue is you keep framing this as "valuation at midpoint versus valuation at floor" like it's a pure negotiation. It's not. The IP is worth what it's worth based on discounted cash flows, market comparables, or whatever methodology the appraiser uses. If the appraiser says $50 million is the right number, that's the number — you don't get to just pick $45 million because it feels safer. But what you do get to control is how much scrutiny you put on the assumptions going into that model. Are the revenue projections coming from the client's business plan or from third-party market data? What discount rate are we using and is it supportable? If we're betting the entire remedial structure on a valuation holding up, we need to be extremely confident in the inputs, not just paying for a Big Four logo on the cover page. Let me flip the question back to you and the client: if we go with curative allocations and model out seven years of activity, what does the distortion actually look like year by year, and how long does it take to cure? The client said he's worried about a massive tax bill in year three if revenue projections hit — but under curative, does he end up in the same place, just with the LPs bearing some interim distortion that gets fixed by year five or six? If the answer is yes, maybe that's the trade-off that makes sense: LPs accept some short-term ceiling rule noise in exchange for not having their deductions depend on a valuation that could get second-guessed. Have we actually run those numbers, or are we just assuming curative doesn't work because it sounds harder?
🏢 Client 2026-03-27 22:02
Look, I appreciate both of you digging into this, but I feel like we're spinning on the valuation risk question when I need to make a practical decision about which method to elect. Let me give you some numbers so we can actually model this out instead of hypothesizing. Year one licensing revenue should be around $12 million, year two around $20 million, ramping up to $35 million by year four if our projections hold. The fund will also have management fee income — we're charging 2% on committed capital, so that's $3 million a year coming into the GP entity, though I assume that's not partnership-level income for curative purposes since it goes to the management company, not the fund. On the portfolio investment side, we're expecting to start seeing exits in year three or four, and those should generate long-term capital gains, but the timing is obviously uncertain. Here's my real concern with what you just said about curative: if the LPs are sitting with distorted allocations for three or four years while we wait for enough non-IP income to cure the problem, that's not "short-term noise" — that's a broken deal. These are pension funds and endowments with their own tax reporting and audit requirements. If their K-1s show income that doesn't track the economics for multiple years running, they're going to escalate it internally and we're going to spend year two and three on investor calls explaining why the tax structure is working as intended even though it looks wrong on paper. I'm not sure that's better than just taking the valuation risk under remedial and being done with it. What I'm hearing is that remedial works mechanically and solves the LP problem, but it requires a bulletproof valuation and creates a tail risk if the IRS comes back later. So let's pressure-test that: if I get a valuation at $50 million and the methodology is solid, what's the actual probability the IRS challenges it in an exam? Are we talking 10% chance, 50% chance? And if they do challenge it, are they realistically going to move the number by more than 10-15%, or is the risk that they try to disallow the whole thing? I need to understand the shape of the risk, not just that it exists.
⚡ Junior Advisor 2026-03-27 22:03
I'm going to be direct with you: nobody can give you a percentage probability on an IRS exam challenge, and anyone who tries is selling you something. What I can tell you is that software IP is a known examination target because the valuation is inherently subjective and the tax consequences of getting it wrong are significant. The IRS has been increasingly aggressive on partnership formation transactions under the Section 707 disguised sale rules and the Section 721 contribution rules, especially where there's a large built-in gain that flows through to deductions for the cash partners. If your fund gets examined — and with $150 million of institutional LPs, you're going to be on someone's radar — the contributed IP value is going to be one of the first things they look at. But here's where I think my colleague is overstating the risk: the IRS challenge isn't going to be "we're disallowing the whole thing" unless you did something truly egregious like contributing IP that doesn't actually exist or using a methodology that's facially absurd. The realistic risk is they bring in their own valuation expert, that expert runs the numbers differently, and they propose an adjustment that knocks your $50 million down to $42 million or $44 million. That's an $6-8 million variance on built-in gain, which means over the life of the fund you've got $6-8 million of remedial allocations that shouldn't have happened. The LPs gave themselves deductions they need to give back, you reported income you need to adjust, and everyone spends a year in Appeals or Tax Court fighting over whose valuation expert is right. It's not Armageddon, but it's exactly the kind of protracted dispute that makes LPs nervous about fund structures. Now let's talk about your numbers, because this is where curative actually starts to look worse than you think. You've got $12 million of licensing revenue in year one, and let's say the operating agreement allocates that based on capital — the LPs put in $150 million, you put in $50 million, so they're entitled to 75% and you're entitled to 25%. That means the LPs should get $9 million and you should get $3 million as their economic split. But under Section 704(c) with the traditional method, we have to allocate enough of that $12 million to you to start eating into your $45 million built-in gain. Let's say we allocate $10 million to you and $2 million to the LPs — now the LPs are $7 million short of where they should be, and that's your ceiling rule distortion in year one alone. You said the management fee income stays at the GP entity level, so that's not available for curative allocations — you're right about that. Which means we're waiting until year three or four when you start seeing capital gains from portfolio exits, and even then we can only use capital items to cure capital distortions, not the ordinary income problem from the licensing revenue. What's the fund's expense structure look like — are there partnership-level operating expenses we could flip around in a curative allocation, or is everything running through the management company?
🛡️ Senior Advisor 2026-03-27 22:03
You're making the ceiling rule distortion sound worse than it actually is by using an aggressive allocation example, and I think that's confusing the client about what traditional method actually produces. If the partnership has $12 million of licensing income in year one and the built-in gain is $45 million, the Section 704(c) regulations don't require you to allocate $10 million to the client immediately — they require you to allocate income in a way that reflects the built-in gain recovery over time as the property produces income. You'd likely allocate something closer to the economic split and let the ceiling rule create a smaller distortion that accumulates over multiple years. The LPs might be short $2-3 million in year one, not $7 million, and that's materially different when we're talking about whether curative can catch up. But here's the bigger problem with your analysis: you keep saying curative doesn't work because the management fees aren't partnership income, and you're half right. The fees go to the management company, not the fund — but does the management company have any economic relationship with the fund that creates allocable items? A lot of these structures have the management company waive fees in exchange for increased GP equity, or they have expense reimbursements that flow through the partnership and create allocable items. We don't know enough about how the client structured the GP entity and the management company to say definitively that there's nothing to work with. If there's any partnership-level expense — fund formation costs, legal fees, portfolio company monitoring expenses — those are items you can tilt in a curative allocation to offset the income distortion. The client asked what the realistic risk is if we go remedial, and I want to anchor this properly: the risk isn't that the IRS is going to challenge every remedial election or that they're going to disallow the structure entirely. The risk is that if they do examine the fund and they do challenge the valuation, the client is going to spend 18-24 months in dispute resolution with a potential seven-figure adjustment at the end, and during that period the LPs are going to receive notices of proposed adjustments on their returns. That creates reputational damage regardless of whether you ultimately win the dispute, because institutional investors have compliance departments that report partnership audits up the chain. I've seen GPs lose their next fundraise because LPs flagged them as high-risk tax operators, even though the underlying dispute settled favorably. So here's the decision as I see it: Option A is remedial, which gives the LPs clean allocations from day one but requires a valuation you're willing to defend in a potentially public dispute, and you need to price that reputational risk. Option B is curative, which creates short-term distortion for the LPs but avoids the valuation dependency, and it only works if we can identify enough partnership items over seven years to actually cure the gap — which we haven't confirmed yet. Which of those risks would you rather manage, and do you have details on the fund's expense structure we can look at to see if curative is even viable?
🏢 Client 2026-03-27 22:03
We are electing the remedial allocation method under Treasury Regulation 1.704-3(d) and contributing the IP at a valuation supported by a Big Four appraisal firm that stress-tests the low end of the reasonable range. The key risk is that the IRS challenges the contribution valuation in an audit, which would require the LPs to amend prior-year returns and give back ordinary deductions they already claimed. Next week I will engage a valuation firm to begin the IP appraisal with instructions to document conservative assumptions on the revenue projections and discount rate.
🔍 IRS Examiner 2026-03-27 22:04
# IRS EXAMINATION MEMORANDUM ## Partnership Contribution & Section 704(c) Remedial Allocation Method ### ISSUE Taxpayer contributed software IP with claimed FMV of $50 million and tax basis of $5 million to a partnership in exchange for 25% capital interest and 20% profits interest (carry), creating $45 million built-in gain. Partnership elected remedial allocation method under Treas. Reg. § 1.704-3(d), generating phantom ordinary deductions to institutional limited partners in years 1-4 corresponding to licensing income allocated to contributing partner. ### GOVERNMENT'S POSITION The Service challenges the $50 million contribution valuation as overstated, which directly invalidates remedial allocations made in subsequent years. Software IP valuations depend heavily on revenue projections and discount rate assumptions that are inherently speculative, particularly for licensing arrangements that have not yet commenced. Even with a "Big Four" appraisal, the methodology likely relies on taxpayer-provided projections that are optimistic and unsubstantiated by historical performance. If the correct FMV at contribution was $40-42 million, the partnership created $6-8 million of excess remedial allocations, meaning limited partners claimed ordinary deductions they were not entitled to receive. The election of remedial method rather than traditional or curative appears designed to accelerate deductions to sophisticated investors while deferring income recognition, which warrants heightened scrutiny under the partnership anti-abuse rule. ### PROPOSED ADJUSTMENT Service proposes adjusting contribution value to $42 million based on independent valuation, reducing built-in gain to $37 million. This requires recalculating all remedial allocations for years 1-4, resulting in approximately $8 million of ordinary deductions being reallocated from limited partners back to the partnership's general income pool. Each limited partner must amend returns for the examination years to reduce ordinary deductions previously claimed, with interest calculated from the original due dates. Accuracy-related penalties under Section 6662(a) apply at 20% to the portion of any underpayment attributable to substantial valuation misstatement, defined under Section 6662(e) as property value claimed at 150% or more of correct amount. Contributing partner's income allocations are correspondingly reduced, and partnership must restate capital accounts under Section 704(b) to reflect corrected contribution value going forward. ### BEST SUPPORTING AUTHORITY *Peracchi v. Commissioner*, 143 F.3d 487 (9th Cir. 1998) — contribution valuation must reflect FMV at time of transfer, and taxpayer bears burden of proving value through reliable contemporaneous evidence. *Canal Corp. v. Commissioner*, 135 T.C. 199 (2010) — partnerships cannot use Section 704(c) methods to create tax benefits not supported by underlying economics; remedial allocations must correspond to actual built-in gain. Treas. Reg. § 1.701-2(b) — partnership anti-abuse rule permits IRS to recast transactions where partnership form is used to reduce substantially the present value of partners' aggregate federal tax liability in a manner inconsistent with Subchapter K intent. ### WEAKNESSES Taxpayer obtained independent third-party valuation prior to contribution and documented conservative assumptions as instructed, which creates strong contemporaneous evidence supporting the claimed value and may satisfy the reasonable cause exception to valuation penalties under Section 6664(c).
Quality Review 4.2 / 5 by Vera
▾
Citation Accuracy 5
Fact Pattern 5
Advisor Disagreement 4
Client Realism 5
IRS Examiner 4
Educational Value 4
⚠ Flagged Citations None flagged. IRC §§ 704(c), 707, 721, 6662(a), 6662(e), 6664(c); Treas. Reg. §§ 1.704-3(d), 1.704-3, 1.701-2(b); Peracchi v. Commissioner, 143 F.3d 487 (9th Cir. 1998); and Canal Corp. v. Commissioner, 135 T.C. 199 (2010) all check out as real and correctly cited.
What Worked The Client is exceptionally realistic — a sophisticated fund manager who pushes back on jargon, demands practical answers about audit probability, and provides concrete numbers when advisors hypothesize. The fact pattern (IP contribution to venture fund with institutional LPs, $45M built-in gain, 704(c) method selection) feels like a real tax director's problem. The technical tension between traditional/curative/remedial methods is well-developed with genuine tradeoffs.
Discussion

Sign in to join the discussion.

Sign in or Create account
No comments yet. Be the first.